Development of questionnaire and assessment of Prameha poorvaroopa in Prediabetes – Cross sectional study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Sample size calculated as 100 based on prevalence of pre-diabetes and Prameha Poorvaroopa are assessed in those individuals who pass the inclusion criteria
研究概览
简要总结
Lack of preventive care during pre-diabetic stage increasing the incidence of diabetes mellitus worldwide. Though there are a number of warning signs of pre-diabetes explained in contemporary health sciences, they are neglected or masked by other health conditions. on the other hand Prameha Poorvaroopas are unique symptomatology explained which appear on the course of manifestation of Prameha. Thus application of Prameha Poorvaroopa lakshanas in identifying warning sign in pre-diabetic patient would help in early diagnosis. As Presently there is no standard questionnaire to assess the classically mentioned Prameha Poorva roopa lakshanas, in this study an attempt will be made to frame the questionnaire based on classically mentioned Prameha Poorva roopa lakshanas and used to asses Prameha Poorvaroopa lakshanas in pre-diabetic patients which helps in early diagnosis.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •The screened patients will be enrolled for the study on diagnosis of pre diabetes by ICMR criteria for diagnosis of pre diabetes.
- •FPG -100-125mg/dl (Fasting is defined as no caloric intake for at least 8 hours.) Or B.
- •2- hours plasma glucose 140-199 mg/dl during an OGTT Or C.
- •HBA1C 5.7-6.4%
- •Participants willing to participate in the study and ready to sign the written consent form.
排除标准
- •Known case of any type of diabetes mellitus
- •Known case of HIV, Hepatitis, Tuberculosis, Pancreatitis, Pancreatic tumor or any other endocrinal disorders
- •Known case of any coexisting illness being capable of masking or promoting the pre diabetic symptoms.
结局指标
主要结局
Sample size calculated as 100 based on prevalence of pre-diabetes and Prameha Poorvaroopa are assessed in those individuals who pass the inclusion criteria
时间窗: The outcome will be assessed at the baseline with the questionnaire specially prepared for the assessment of Prameha Poorvaroopa in prediabetes, further follow up will not be done
次要结局
- Assessing pre-diabetic patients with framed questionnaire & recording prevalence of each Prameha Poorvaroopa in pre-diabetic individual(The outcome will be assessed at the baseline with the questionnaire specially prepared for the assessment of Prameha Poorvaroopa in prediabetes, further follow up will not be done)
研究者
Dr Nayana G
Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Hassan